Participated · Seed · Mar 2026

Theta Neurotech is developing a non-invasive wearable EEG patch aimed at forecasting seizures. The company pivoted from a broader consumer "Fitbit for the brain" concept toward a medical wedge focused on epilepsy after identifying clinical demand and behavioral considerations for EEG wearables. Theta has raised $2 million in pre-seed funding to support device development, machine-learning research, and an exploratory clinical study. Co-founders Truman Pierson and Christopher Fitz lead the company. The market for seizure monitoring includes invasive and non-invasive competitors, but non-invasive seizure forecasting remains early-stage and challenging. Several rivals are running exploratory studies, and none have yet reached patients.

Participated · Series A · Jun 2021

Allotrope Medical develops StimSite™, an FDA-cleared smooth muscle stimulation device that leverages surgeons’ existing laparoscopic and robotic instruments to identify and locate the ureter during pelvic operations. The company is led by founder and CEO Albert Huang, MD, and is based in Houston, TX. StimSite™ is positioned as an intraoperative tool to reduce ureteral injury risk by improving ureter visualization. Allotrope Medical intends to use newly raised funds to accelerate its commercialization plans. The company closed a $4M Series A financing to support those efforts. No operating metrics were disclosed in the article. Allotrope Medical is a Houston-based medical device company developing an innovative surgical device intended to identify ureters and decrease the rate of injury during surgery. The company is led by Founder and CEO Albert Huang MD and is advancing the device through continued development funded by a recent financing. The round was led by Houston Health Ventures with syndication support from the Houston Angel Network; the amount raised was undisclosed. In conjunction with the financing, David Franklin, Managing Director of HHV, will join the Board of Directors alongside Donald Gonzales MD (Founder/CMO, Spirox Inc.) and Mira Sahney (former SVP and GM, Gynecology and ENT Divisions, Smith & Nephew). Allotrope said it will use the funds to continue device development and is targeting commercial availability in late 2018. No operating metrics or prior funding details were disclosed in the article.

Participated · Series A · May 2021

Astrocyte Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company based in Groton, Conn., focused on developing novel cerebroprotective therapeutics. Its lead candidate, AST-004, has shown efficacy across diverse small and large animal brain injury models and is being evaluated for a broad array of acute brain injuries including stroke and traumatic brain injury. Astrocyte is currently conducting Phase 1B clinical safety studies of AST-004 and is preparing for Phase 2 efficacy studies in 2024. The company is also assessing AST-004 in preclinical models of Alzheimer's disease to explore potential benefits in chronic neurodegenerative conditions. The announced financing will be used to accelerate clinical development of AST-004 and further preclinical assessment in Alzheimer's disease. Astrocyte positions its approach as a potential way to reduce astrocyte-induced excess inflammation and provide neuroprotection in combination and precision medicine strategies. Astrocyte Pharmaceuticals is advancing novel neuroprotective therapeutics intended to reduce brain injury from stroke, traumatic brain injury, concussion and other neurodegenerative conditions. Its lead therapeutic is based on technology licensed from the University of Texas Health Science Center at San Antonio. The company completed a Series A financing that raised $6 million. Proceeds from the round will be used to advance the lead program into Phase 1 human trials. Astrocyte describes itself as focused on addressing an unmet need for drugs that limit neurodegenerative brain injury. No operating metrics were disclosed in the article. Astrocyte Pharmaceuticals is a privately held drug development company focused on small‑molecule neuroprotective therapeutics for stroke, traumatic brain injury/concussion, and neurodegenerative disorders. The company is committed to proving the neuroprotective benefits of enhancing astrocyte function and advancing related therapeutic agents. Its lead program is AST‑004, which the company and investors cite as having promising preclinical efficacy and a novel mechanism of action. Astrocyte completed a Pre‑A financing that raised over $2.3M to support its development plans. The company intends to use proceeds to advance its first program into clinical studies. The press release also notes research support from the National Institute of Neurological Disorders and Stroke (NIH) and the Department of Defense under specific award numbers.

Participated · Equity · May 2021

Osteoboost Health Inc. develops a wearable Class II prescription device worn around the hips that delivers low-magnitude vibration therapy to the lumbar spine and hips as a non-drug treatment for low bone density and osteopenia, particularly in postmenopausal women. The treatment approach is based on research originally funded by NASA and, in a double-blind trial at the University of Nebraska Medical Center, users who adhered to at least three 30-minute sessions per week for 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, per the company. The device received a Breakthrough Device designation in 2024 and was later cleared via the FDA De Novo pathway; the company began shipping in May. Since launch it has been prescribed by more than 2,500 physicians, including clinicians at over 30 academic medical centers. The company was also named to TIME’s 2025 list of Best Inventions. Osteoboost plans to use the new financing to scale manufacturing, expand clinical research, and broaden commercialization.

Participated · Seed · Sep 2020

Spine Align is a Baltimore, MD-based medical device company developing a portfolio of intraoperative products that assess and assist with corrective surgeries for spinal alignment. Its flagship product, LiveAlign, is designed to enable surgeons to measure, visualize and adjust patients' spinal alignment during surgery. The company closed a $1.75M seed round to support development efforts to achieve FDA 510(k) clearance for LiveAlign in 2021. Spine Align was co-founded by Amir Soltanianzadeh (CEO), Dr. David Gullotti (CTO) and Dr. Nicholas Theodore. The venture originated as a spinout from the Johns Hopkins Center for Bioengineering Innovation and Design.